MedPath

ePrime: Evaluation of Magnetic Resonance (MR) Imaging to Predict Neurodevelopmental Impairment in Preterm Infants

Conditions
Cerebral Palsy
Registration Number
NCT01049594
Lead Sponsor
Imperial College London
Brief Summary

Preterm infants face an uncertain future because premature birth often leads to problems with brain development and can cause cerebral palsy.

A trial needs to be done to see if Magnetic Resonance Imaging (MRI) helps families and professionals by predicting long term problems more accurately, allowing better targeting of care to children with problems and reassuring the parents of normal babies.

This programme will provide the evidence-base for the National Health System (NHS) policy on the use of magnetic resonance imaging of the brain for preterm infants.

Detailed Description

The trial will determine very accurately how well MRI predicts long-term problems, and it will assess whether it makes parents more or less anxious about their babies, and whether they seek more or less help in the first couple of years after birth,and see if the total cost to the NHS is increased by using MRI. It will also check up if there is a better way to do ultrasound examinations, and do a survey to see how much MRI is used in the United Kingdon (UK) and whether hospitals think they could provide it.

The core of the project is a study of preterm babies who will be referred to a specialist centre to have both ultrasound and MRI scans. Half the parents will be told the results of the MRI and half the parents the ultrasound. The programme will then ask them to fill in questionnaires or be interviewed about their stress levels and the amount of support they seek for their children until they are two years old, when the babies will be examined to see if MRI predicted their outcome accurately.

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
625
Inclusion Criteria

-Delivery at less than 33 completed weeks of gestation, estimated from early fetal ultrasonographic measurements as recommended in the National Institute of Clinical Excellence Guidelines: Antenatal Care for the Healthy Woman

Exclusion Criteria
  • Prior MR imaging
  • Major Congenital Malformations
  • Presence of Metallic Implants

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
This programme will provide the evidence-base for NHS policy on the use of magnetic resonance (MR) imaging of the brain for preterm infants.5 years

1. Determine with high precision the sensitivity and specificity of cerebral MR imaging for predicting neurodevelopmental impairment in the context of the NHS.

2. Use a randomised design to compare the effect of MR and ultrasound imaging on total healthcare usage and costs, and assess its effect on unplanned and planned care.

3. Compare the influence of MR- and ultrasound-based information on parental perceptions, stress and coping.

4. Compare routine local bedside with specialist centralised ultrasound imaging.

5. Survey current MR use and capacity in the NHS.

6. Develop further novel MR methods to predict neurodevelopmental impairment.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (13)

Northwick Park Hospital

πŸ‡¬πŸ‡§

London, United Kingdom

Barnet General Hospital

πŸ‡¬πŸ‡§

London, United Kingdom

Kingston Hospital NHS Trust

πŸ‡¬πŸ‡§

London, United Kingdom

St George's Healthcare NHS Trust

πŸ‡¬πŸ‡§

London, United Kingdom

Queen Charlotte's & Chelsea Hospital

πŸ‡¬πŸ‡§

London, United Kingdom

Croydon University Hospital

πŸ‡¬πŸ‡§

London, United Kingdom

West Middlesex University Hospital

πŸ‡¬πŸ‡§

London, United Kingdom

Guys & St Thomas NHS Trust Foundation

πŸ‡¬πŸ‡§

London, United Kingdom

Ealing Hospital NHS Trust

πŸ‡¬πŸ‡§

London, United Kingdom

Epsom and St Helier University Hospital

πŸ‡¬πŸ‡§

London, United Kingdom

Hillingdon Hopsital

πŸ‡¬πŸ‡§

London, United Kingdom

St. Peter's Hospital

πŸ‡¬πŸ‡§

Surrey, United Kingdom

St Marys Hospital

πŸ‡¬πŸ‡§

London, United Kingdom

Β© Copyright 2025. All Rights Reserved by MedPath